Review
Pancreatic cancer treatment
: Recent evidence for long-term survival
2020 Volume 35 Issue 2 Pages 193-200
Details
2020 Volume 35 Issue 2 Pages 193-200
The 5-year survival of patients with pancreatic cancer is so dismal that it is regarded as the most aggressive gastrointestinal cancer. Surgical resection concomitant with adjuvant therapy is the only potential cure for patients with pancreatic cancer, and neoadjuvant therapy is also being used. The JASPAC01 trial reported a remarkable effect of S-1 as adjuvant therapy which has been the standard treatment in Japan. Recently, the adjuvant use of FOLFIRINOX was reported. Following the results of the Prep-02/JSAP-05 trial, Gemcitabine and S-1 will be the standard option for neoadjuvant therapy in patients with resectable pancreatic cancer. The first randomized trial showed a benefit of neoadjuvant therapy in patients with borderline resectable pancreatic cancer. The benefit of neoadjuvant therapy in patients with locally advanced pancreatic cancer remains an unsolved clinical issue.
